Olendalizumab  (Synonyms: ALXN1007)

Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Complement protein C5a^[1]

Olendalizumab can be used as an biotinylated capture reagent, with working concentration of 100 μg/mL in Bioaffy wash 1, while the AlexaFluor labeled anti-C5a clone 2942 is 4 μg/mL in Rexxip F^[1].
The members of the complement system such as C3, C5a, C5b-9, including receptors such as C3aR and C5aR mediate the lung injury following viral infection. Moreover, C5/C5a is only non-silent complement in corona virus-induced lung injury. Olendalizumab is the potent C5a inhibitor^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2210314-30-8

[Olendalizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2-G4-kappa

• [1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106.  [Content Brief]

  [2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.